1.	Phase III Randomized Study of Cytarabine With Versus Without VNP40101M in Patients With Acute Myeloid Leukemia in First Relapse Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-037, NCT00112554
2.	Phase I/II Study of VNP40101M in Patients With Richter Syndrome or Refractory or Relapsed Chronic Lymphocytic Leukemia or Other Lymphoproliferative Disease Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-041, MDA-2005-0249, NCT00304005
3.	Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 60 and over Sponsor: Other Protocol IDs: 0702009008, VNP40101M, NCT00655395
4.	Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Other Protocol IDs: CDR0000634230, IPC-LAM-HR, IPC-2006-007, INCA-RECF0902, EUDRACT-2007-001082-15, LAM-HR, NCT00840684
5.	Phase II Study of VNP40101M in Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-033, NCT00083187
6.	Phase II Study of VNP40101M in Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-039, NCT00282022
7.	Phase II Study of VNP40101M Followed By Cytarabine in Older Patients With Poor-Risk, De Novo Acute Myeloid Leukemia Phase: Phase II Type: Treatment Status: Closed Age: 60 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-043, NCT00354276, EUDRACT-2006-001853-89
8.	Phase I Study of VNP40101M in Patients With Advanced Solid Tumors or Lymphomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-011, NCI-V01-1669, NCT00025129
9.	Phase I Study of VNP40101M in Patients With Relapsed or Refractory Leukemia or Poor-Risk Myelodysplastic Syndromes Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-029, MDA-DM-02202, NCT00049686
10.	Phase I Study of VNP40101M in Patients With Advanced or Metastatic Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-028, YALE-HIC-16775, NCT00049699
11.	Phase I Study of VNP40101M and Cytarabine in Patients With Hematologic Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: VION-CLI-034, MDA-2003-0326, NCT00070538
12.	Phase I Study of Temozolomide and VNP40101M in Patients With Relapsed or Refractory Leukemias Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VION-CLI-036, CWRU-050419, NCT00098436
13.	Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies Phase: Phase I Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 2005-0844, NCT00521859
14.	VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors Phase: Phase I Type: Treatment Status: Completed Age: 21 and under Sponsor: NCI, Other Protocol IDs: CDR0000396779, PBTC-017, VION-VNP40101M, NCT00098761